| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
EIKN
Eikon Therapeutics, Inc.
|
Oct 16, 2026 | BUY |
Buy
+229.0% avg upside
6 analysts
|
$23.00
210.06% Upside
|
+0.0% | Β· |
|
KTTA
Pasithea Therapeutics Corp
|
Oct 05, 2026 | BUY |
Strong Buy
+3495.3% avg upside
3 analysts
|
$3.00
614.37% Upside
|
+2.9% | Β· |
|
MBRX
Moleculin Biotech
|
Sep 29, 2026 | BUY |
Strong Buy
+4204.6% avg upside
5 analysts
|
$3.00
969.93% Upside
|
-29.7% | Β· |
|
SE:CANTA
Cantargia AB
|
Sep 21, 2026 | BUY |
Strong Buy
+818.9% avg upside
1 analyst
|
$12.00
818.90% Upside
|
-10.6% | Β· |
|
TVRD
Tvardi Therapeutics
|
Aug 21, 2026 | BUY |
Strong Buy
+1618.6% avg upside
24 analysts
|
$9.00
791.05% Upside
|
-42.5% | Β· |
|
CRIS
Curis
|
Aug 17, 2026 | BUY |
Strong Buy
+3097.6% avg upside
12 analysts
|
$43.00
10462.60% Upside
|
-77.2% | Β· |
|
KAPA
Kairos Pharma, Ltd.
|
Aug 13, 2025 | BUY |
Strong Buy
+4847.6% avg upside
4 analysts
|
$12.00
1895.73% Upside
|
-66.4% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.